title: Effects of Rab27a on proliferation, invasion, and anti-apoptosis in human glioma cell.
abstract: This study aims to investigate the relationship between Rab27a and the characteristics of glioma cell U251 such as proliferation, apoptosis, and invasion and to provide an experimental basis for future therapy in human glioma. Recombinant plasmid of pcDNA3.1-Rab27a was constructed and transfected into U251 cells with the help of Lipofectamine™2000. The expression of Rab27a was detected by Western blot. Cell viability, cell cycle, cell apoptosis, and cell migration were analyzed, respectively, by (3-(4,5)-dimethylthi-azol-2-yl)-2,5-diphenytetrazolium bromide (MTT) assay, flow cytometry, and Transwell invasion chamber methods. Meanwhile, the effect of Rab27a on secretion of cathepsin D in U251 cells was also examined. With the help of luciferase reporter assay system, the relationship between miR-124 and gene Rab27a expression was explored. Western blot showed that the expression of Rab27a was significantly increased in pcDNA3.1-Rab27a transfection group (p < 0.01) and that was significantly decreased in Rab27a-shRNA transfection group (p < 0.01) compared with control group. MTT assay, flow cytometry, and Transwell invasion chamber experiment indicated that cell viability (p < 0.01), proliferation index (p < 0.05), and invasion ability (p < 0.01) were improved significantly in pcDNA3.1-Rab27a transfection group compared with control group and that cell viability (p < 0.01), proliferation index (p < 0.05), and invasion ability (p < 0.01) were reduced markedly in Rab27a-shRNA transfection group compared with control group. The apoptosis analysis by flow cytometry demonstrated that the ratio of apoptosis in pcDNA3.1-Rab27a transfection group was significantly lower than that in control group (p < 0.05) and the ratio was notably higher in Rab27a-shRNAtransfection group than that in the control group. Cathepsin D activity assay indicated that the release of cathepsin D was enhanced in pcDNA3.1-Rab27a transfection group compared to that in the control group (p < 0.05). Rab27a could increase the glioma cell ability, promote proliferation and invasion, and suppress cell apoptosis. The above-stated effects of Rab27a possibly were exerted by increasing the secretion of cathepsin D and regulated by miR-124. In addition, the inhibition of expression of Rab27a perhaps benefited the therapy for glioma patients.
authors.affiliation: Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, 230061, People's Republic of China.
authors.forename: Xiuwei
authors.initials: X
authors.lastname: Wu
authors.forename: Anla
authors.initials: A
authors.lastname: Hu
authors.forename: Mingjun
authors.initials: M
authors.lastname: Zhang
authors.forename: Zhendong
authors.initials: Z
authors.lastname: Chen
mesh_terms: D017209:Apoptosis / Q000235:genetics*; D002402:Cathepsin D / Q000235:genetics / Q000378:metabolism; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D002470:Cell Survival / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D005910:Glioma / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D009361:Neoplasm Invasiveness / Q000235:genetics*; D034622:RNA Interference; D034741:RNA, Small Interfering; D014162:Transfection; D020691:rab GTP-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D000075745:rab27 GTP-Binding Proteins
chemical_list: C509207:MIRN124 microRNA, human; D035683:MicroRNAs; D034741:RNA, Small Interfering; D000075745:rab27 GTP-Binding Proteins; C533922:CTSD protein, human; D002402:Cathepsin D; C066694:RAB27A protein, human; D020691:rab GTP-Binding Proteins
references.citation: Expert Rev Proteomics. 2011 Apr;8(2):211-20
references.pmid: 21501014
references.citation: Eur J Cancer. 1994;30A(5):670-4
references.pmid: 8080685
references.citation: Cell Mol Life Sci. 2013 Jun;70(12):2175-90
references.pmid: 23307072
references.citation: Genes Cancer. 2012 Jan;3(1):3-15
references.pmid: 22893786
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11821-7
references.pmid: 16882731
references.citation: Cell Signal. 2011 Mar;23(3):516-21
references.pmid: 20851765
references.citation: Physiol Rev. 2011 Jan;91(1):119-49
references.pmid: 21248164
references.citation: Oncogene. 2014 Jan 23;33(4):514-24
references.pmid: 23334332
references.citation: PLoS One. 2012;7(7):e41160
references.pmid: 22844437
references.citation: Folia Histochem Cytobiol. 2011;49(4):547-57
references.pmid: 22252749
references.citation: Semin Cell Dev Biol. 2011 Feb;22(1):57-68
references.pmid: 21147240
references.citation: Cell Mol Life Sci. 2010 Oct;67(20):3449-65
references.pmid: 20582450
references.citation: J Cell Sci. 2012 Sep 15;125(Pt 18):4278-87
references.pmid: 22718352
references.citation: Cancer Res. 2012 Oct 1;72(19):4920-30
references.pmid: 22865453
references.citation: Behav Brain Res. 2013 Jan 15;237:223-9
references.pmid: 23026376
references.citation: Curr Neurol Neurosci Rep. 2011 Jun;11(3):313-9
references.pmid: 21327735
references.citation: Patient Educ Couns. 2013 May;91(2):141-53
references.pmid: 23218925
references.citation: Curr Pharm Biotechnol. 2012 Sep;13(11):2299-307
references.pmid: 21605067
references.citation: Prostate. 2013 Apr;73(5):476-88
references.pmid: 22996917
references.citation: Biochem J. 2011 Jul 1;437(1):13-24
references.pmid: 21668412
references.citation: BMC Microbiol. 2012 Nov 19;12:265
references.pmid: 23164453
references.citation: Mol Med Rep. 2012 Sep;6(3):459-65
references.pmid: 22751839
references.citation: Protein Cell. 2011 Jan;2(1):13-25
references.pmid: 21337006
references.citation: Dig Dis. 2012;30(3):255-67
references.pmid: 22722550
references.citation: Clin Genet. 2011 Oct;80(4):305-18
references.pmid: 21651512
references.citation: Chemphyschem. 2009 Nov 9;10(16):2769-76
references.pmid: 19774545
references.citation: FASEB J. 2012 Dec;26(12):5172-81
references.pmid: 22898924
references.citation: Anticancer Agents Med Chem. 2012 Feb;12(2):172-5
references.pmid: 22292775
references.citation: Curr Opin Cell Biol. 2011 Aug;23(4):404-12
references.pmid: 21450449
references.citation: Glia. 2013 Jan;61(1):91-103
references.pmid: 22653784
references.citation: Biochem Soc Trans. 2011 Oct;39(5):1202-6
references.pmid: 21936789
references.citation: Cancer Biomark. 2010;7(1):47-64
references.pmid: 21045264
references.citation: Semin Cell Dev Biol. 2011 Feb;22(1):18-26
references.pmid: 20643221
references.citation: J Neurooncol. 2013 Mar;112(1):59-66
references.pmid: 23299462
references.citation: Trends Endocrinol Metab. 2011 Mar;22(3):110-6
references.pmid: 21216617
references.citation: PLoS One. 2012;7(9):e45910
references.pmid: 23029308
references.citation: Islets. 2012 Sep-Oct;4(5):354-8
references.pmid: 23114750
references.citation: Semin Cell Dev Biol. 2011 Feb;22(1):48-56
references.pmid: 20951823
references.citation: J Natl Cancer Inst. 2010 Jun 16;102(12):866-80
references.pmid: 20484105
references.citation: Biochem Soc Trans. 2012 Dec 1;40(6):1383-8
references.pmid: 23176485
references.citation: Nat Rev Mol Cell Biol. 2009 Aug;10(8):513-25
references.pmid: 19603039
references.citation: Nat Med. 2012 Jun;18(6):883-91
references.pmid: 22635005
references.citation: Biochem Soc Trans. 2012 Dec 1;40(6):1398-403
references.pmid: 23176488
references.citation: J Neuroimmunol. 2010 Jul 27;224(1-2):8-12
references.pmid: 20656128
references.citation: Br J Cancer. 2013 Jan 15;108(1):64-71
references.pmid: 23321511
references.citation: Int J Oncol. 2013 Mar;42(3):1081-7
references.pmid: 23337938
references.citation: Int J Proteomics. 2012;2012:245819
references.pmid: 22919486
references.citation: Mol Cancer Res. 2008 Mar;6(3):372-82
references.pmid: 18337447
references.citation: J Neurooncol. 2013 Apr;112(2):141-52
references.pmid: 23344789
references.citation: Expert Opin Biol Ther. 2011 Jun;11(6):799-806
references.pmid: 21521146